S&P 500   3,916.23 (-4.22%)
DOW   31,419.51 (-3.78%)
QQQ   291.13 (-4.91%)
AAPL   140.68 (-5.74%)
MSFT   254.63 (-4.57%)
FB   193.11 (-4.69%)
GOOGL   2,255.52 (-3.17%)
AMZN   2,133.04 (-7.56%)
TSLA   706.71 (-7.21%)
NVDA   169.21 (-6.91%)
BABA   87.26 (-5.14%)
NIO   15.71 (-5.53%)
AMD   96.02 (-6.29%)
CGC   5.60 (-4.92%)
MU   71.11 (-4.52%)
T   20.18 (-1.90%)
GE   75.23 (-1.53%)
F   12.75 (-5.76%)
DIS   104.39 (-3.91%)
AMC   12.72 (-1.40%)
PFE   50.28 (-2.06%)
PYPL   77.04 (-3.40%)
NFLX   177.26 (-6.98%)
S&P 500   3,916.23 (-4.22%)
DOW   31,419.51 (-3.78%)
QQQ   291.13 (-4.91%)
AAPL   140.68 (-5.74%)
MSFT   254.63 (-4.57%)
FB   193.11 (-4.69%)
GOOGL   2,255.52 (-3.17%)
AMZN   2,133.04 (-7.56%)
TSLA   706.71 (-7.21%)
NVDA   169.21 (-6.91%)
BABA   87.26 (-5.14%)
NIO   15.71 (-5.53%)
AMD   96.02 (-6.29%)
CGC   5.60 (-4.92%)
MU   71.11 (-4.52%)
T   20.18 (-1.90%)
GE   75.23 (-1.53%)
F   12.75 (-5.76%)
DIS   104.39 (-3.91%)
AMC   12.72 (-1.40%)
PFE   50.28 (-2.06%)
PYPL   77.04 (-3.40%)
NFLX   177.26 (-6.98%)
S&P 500   3,916.23 (-4.22%)
DOW   31,419.51 (-3.78%)
QQQ   291.13 (-4.91%)
AAPL   140.68 (-5.74%)
MSFT   254.63 (-4.57%)
FB   193.11 (-4.69%)
GOOGL   2,255.52 (-3.17%)
AMZN   2,133.04 (-7.56%)
TSLA   706.71 (-7.21%)
NVDA   169.21 (-6.91%)
BABA   87.26 (-5.14%)
NIO   15.71 (-5.53%)
AMD   96.02 (-6.29%)
CGC   5.60 (-4.92%)
MU   71.11 (-4.52%)
T   20.18 (-1.90%)
GE   75.23 (-1.53%)
F   12.75 (-5.76%)
DIS   104.39 (-3.91%)
AMC   12.72 (-1.40%)
PFE   50.28 (-2.06%)
PYPL   77.04 (-3.40%)
NFLX   177.26 (-6.98%)
S&P 500   3,916.23 (-4.22%)
DOW   31,419.51 (-3.78%)
QQQ   291.13 (-4.91%)
AAPL   140.68 (-5.74%)
MSFT   254.63 (-4.57%)
FB   193.11 (-4.69%)
GOOGL   2,255.52 (-3.17%)
AMZN   2,133.04 (-7.56%)
TSLA   706.71 (-7.21%)
NVDA   169.21 (-6.91%)
BABA   87.26 (-5.14%)
NIO   15.71 (-5.53%)
AMD   96.02 (-6.29%)
CGC   5.60 (-4.92%)
MU   71.11 (-4.52%)
T   20.18 (-1.90%)
GE   75.23 (-1.53%)
F   12.75 (-5.76%)
DIS   104.39 (-3.91%)
AMC   12.72 (-1.40%)
PFE   50.28 (-2.06%)
PYPL   77.04 (-3.40%)
NFLX   177.26 (-6.98%)
NASDAQ:GOSS

Gossamer Bio (GOSS) Stock Forecast, Price & News

$7.80
-0.84 (-9.72%)
(As of 05/18/2022 03:21 PM ET)
Add
Compare
Today's Range
$7.75
$8.59
50-Day Range
$6.41
$9.97
52-Week Range
$6.28
$14.30
Volume
17,268 shs
Average Volume
1.38 million shs
Market Capitalization
$601.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.12
30 days | 90 days | 365 days | Advanced Chart
Receive GOSS News and Ratings via Email

Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter.

Gossamer Bio logo

About Gossamer Bio

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GOSS
Fax
N/A
Employees
185
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$1.59 per share

Profitability

Net Income
$-234 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
70,948,000
Market Cap
$601.54 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/10/2022
Today
5/18/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.20 out of 5 stars

Medical Sector

354th out of 1,426 stocks

Pharmaceutical Preparations Industry

142nd out of 680 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -













Gossamer Bio (NASDAQ:GOSS) Frequently Asked Questions

Is Gossamer Bio a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Gossamer Bio stock.
View analyst ratings for Gossamer Bio
or view top-rated stocks.

When is Gossamer Bio's next earnings date?

Gossamer Bio is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Gossamer Bio
.

How were Gossamer Bio's earnings last quarter?

Gossamer Bio, Inc. (NASDAQ:GOSS) released its quarterly earnings data on Tuesday, May, 10th. The company reported ($0.76) earnings per share for the quarter, beating analysts' consensus estimates of ($0.77) by $0.01.
View Gossamer Bio's earnings history
.

What price target have analysts set for GOSS?

8 brokerages have issued twelve-month price objectives for Gossamer Bio's stock. Their forecasts range from $10.00 to $24.00. On average, they anticipate Gossamer Bio's stock price to reach $17.50 in the next year. This suggests a possible upside of 123.8% from the stock's current price.
View analysts' price targets for Gossamer Bio
or view top-rated stocks among Wall Street analysts.

Who are Gossamer Bio's key executives?
Gossamer Bio's management team includes the following people:
  • Mr. Faheem Hasnain, Co-Founder, CEO, Pres & Chairman (Age 64, Pay $895.56k)
  • Mr. Bryan Giraudo, COO & CFO (Age 46, Pay $651.8k) (LinkedIn Profile)
  • Mr. Christian Waage, Exec. VP of Technical Operations & Admin. (Age 55, Pay $583.16k)
  • Dr. Laura L. Carter Ph.D., Chief Scientific Officer (Age 55)
  • Ms. Deanna Weber, Sr. VP of HR
  • Dr. Richard Aranda M.D., Chief Medical Officer (Age 62)
  • Ms. Caryn L. Peterson, Exec. VP of Regulatory Affairs (Age 63)
  • Dr. Larry Zisman M.D., Sr. Director of Clinical Devel.
  • Dr. Robert F. Roscigno, VP of Clinical Devel. (Age 56)
  • Mr. Mario Orlando, VP of Commercial New Product Planning
What other stocks do shareholders of Gossamer Bio own?
When did Gossamer Bio IPO?

(GOSS) raised $230 million in an initial public offering (IPO) on Friday, February 8th 2019. The company issued 14,400,000 shares at $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI served as the underwriters for the IPO.

What is Gossamer Bio's stock symbol?

Gossamer Bio trades on the NASDAQ under the ticker symbol "GOSS."

Who are Gossamer Bio's major shareholders?

Gossamer Bio's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.33%), BlackRock Inc. (6.91%), Federated Hermes Inc. (4.57%), State Street Corp (4.29%), Emerald Advisers LLC (2.55%) and Kynam Capital Management LP (2.38%). Company insiders that own Gossamer Bio stock include Bryan Giraudo, Caryn Peterson, Faheem Hasnain, Laura Carter, Luisa Salter-Cid and Waage Christian.
View institutional ownership trends for Gossamer Bio
.

Which major investors are selling Gossamer Bio stock?

GOSS stock was sold by a variety of institutional investors in the last quarter, including Woodline Partners LP, Parkman Healthcare Partners LLC, Emerald Mutual Fund Advisers Trust, BlackRock Inc., Endurant Capital Management LP, Ally Bridge Group NY LLC, Walleye Trading LLC, and Royal Bank of Canada. Company insiders that have sold Gossamer Bio company stock in the last year include Caryn Peterson, Faheem Hasnain, Laura Carter, and Waage Christian.
View insider buying and selling activity for Gossamer Bio
or view top insider-selling stocks.

Which major investors are buying Gossamer Bio stock?

GOSS stock was bought by a variety of institutional investors in the last quarter, including Kynam Capital Management LP, Federated Hermes Inc., Eversept Partners LP, Goldman Sachs Group Inc., Emerald Advisers LLC, Alyeska Investment Group L.P., Renaissance Technologies LLC, and Walleye Capital LLC. Company insiders that have bought Gossamer Bio stock in the last two years include Bryan Giraudo, Faheem Hasnain, and Waage Christian.
View insider buying and selling activity for Gossamer Bio
or or view top insider-buying stocks.

How do I buy shares of Gossamer Bio?

Shares of GOSS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gossamer Bio's stock price today?

One share of GOSS stock can currently be purchased for approximately $7.82.

How much money does Gossamer Bio make?

Gossamer Bio has a market capitalization of $603.08 million. The company earns $-234 million in net income (profit) each year or ($3.10) on an earnings per share basis.

How many employees does Gossamer Bio have?

Gossamer Bio employs 185 workers across the globe.

What is Gossamer Bio's official website?

The official website for Gossamer Bio is www.gossamerbio.com.

How can I contact Gossamer Bio?

Gossamer Bio's mailing address is 3013 SCIENCE PARK, SAN DIEGO CA, 92121. The company can be reached via phone at (858) 684-1300 or via email at [email protected].

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.